Xenazine — Competitive Intelligence Brief

Xenazine (TETRABENAZINE) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vesicular Monoamine Transporter 2 Inhibitor [EPC]. Area: Metabolic.

marketed Vesicular Monoamine Transporter 2 Inhibitor [EPC] Synaptic vesicular amine transporter Metabolic Small molecule

Target snapshot

Xenazine (TETRABENAZINE) — Bausch Health. Xenazine works by blocking the reuptake of dopamine and other neurotransmitters into synaptic vesicles, reducing their release and alleviating symptoms of Huntington's chorea.

Comparator set (5 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Xenazine TARGET	TETRABENAZINE	Bausch Health	marketed	Vesicular Monoamine Transporter 2 Inhibitor [EPC]	Synaptic vesicular amine transporter	2008-01-01
Austedo	DEUTETRABENAZINE	Teva	marketed		Synaptic vesicular amine transporter	2017-01-01
Raunormin	DESERPIDINE		marketed	Catecholamine-depleting Sympatholytic	Synaptic vesicular amine transporter	1957-01-01
Moderil	RESCINNAMINE	Pfizer	marketed	rescinnamine	Synaptic vesicular amine transporter	1956-01-01
Vyvanse	Vyvanse	Vanderbilt University	marketed		Sodium-dependent dopamine transporter, Sodium-dependent noradrenaline transporter, Synaptic vesicular amine transporter
Ingrezza	valbenazine	Neurocrine	marketed		Potassium voltage-gated channel subfamily H member 2, Synaptic vesicular amine transporter, Synaptic vesicular amine transporter

Recent regulatory actions (last 90 days)

• 2026-04-08 — Ingrezza · FDA · approved · US · Neurocrine

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vesicular Monoamine Transporter 2 Inhibitor [EPC] class)

1. Bausch Health · 1 drug in this class